Earnings History Data for Atara Biotherapeutics, Inc. (ATRA) - NYSE NASDAQ

To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.

For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.

See the full list of available companies here.

Atara Biotherapeutics, Inc.

Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing therapeutics for serious unmet medical needs, with an initial focus on muscle wasting conditions and oncology. The company's lead programs are focused on myostatin and activin, members of the TGF-beta family of proteins that have demonstrated the potential to have therapeutic benefit in a number of clinical indications. Its lead product candidate is PINTA 745, which is in a Phase II clinical trial for the treatment of protein-energy wasting in end-stage renal disease patients. Atara Biotherapeutics, Inc. is headquartered in Brisbane, California.

Release Date	Time	Est. Time	Symbol	Name	Market Cap (M)	Rep. EPS	Est. EPS	Last years EPS	SeekingAlpha Headline	Price	Change	Ext. Hours Price	Ext. Hours Change	52 Week Range	Volume	Avg. Volume	Ext. Hours Volume
07-03-2025	AH		ATRA	Atara Biotherapeutics	42.00	-1.19	-3.82	0.00	Atara Biotherapeutics GAAP EPS of -$1.19 beats by $2.39, revenue of $32.75M beats by $16.1M [3/7/2025 4:06 PM]	6.22	-0.68 (-9.85%)	7.59	0.69 (10.00%)	5.40 - 20.82	139,033	70,000	1,522
Atara Biotherapeutics: Q4 Earnings Snapshot [2025-03-07 04:16PM] Atara Biotherapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Operational Progress [2025-03-07 04:01PM] Atara Biotherapeutics (ATRA) Reports Q4 Loss, Tops Revenue Estimates [2025-03-07 05:10PM]
12-11-2024	AH		ATRA	Atara Biotherapeutics, Inc.	55.59	-2.93	-3.77	-16.50	Atara Biotherapeutics GAAP EPS of -$2.93 beats by $17.16, revenue of $40.19M beats by $5.02M [11/12/2024 4:55 PM]	14.31	2.64 (22.62%)	12.00	0.33 (2.83%)	4.97 - 39.50	295,234	160,000	2,110
Atara Biotherapeutics GAAP EPS of -$2.93 beats by $17.16, revenue of $40.19M beats by $5.02M [11/12/2024 4:55 PM] Atara Biotherapeutics: Q3 Earnings Snapshot [2024-11-12 04:13PM] Atara Biotherapeutics Announces Third Quarter 2024 Financial Results and Operational Progress [2024-11-12 04:01PM] Atara Biotherapeutics (ATRA) Reports Q3 Loss, Tops Revenue Estimates [2024-11-12 05:15PM]
12-08-2024	AH		ATRA	Atara Biotherapeutics	37.00	-3.10	-1.25	0.00	Atara Biotherapeutics GAAP EPS of -$3.10 misses by $1.54, revenue of $28.64M misses by $8.45M [8/12/2024 5:34 PM]	8.10	0.33 (4.25%)	0.0	0.0 (0.00%)	4.97 - 52.25	50,496	50,000	0
Atara Biotherapeutics GAAP EPS of -$3.10 misses by $1.54, revenue of $28.64M misses by $8.45M [8/12/2024 5:34 PM]
09-05-2024	AH		ATRA	Atara Biotherapeutics	73.00	-0.23	-0.37	0.00	Atara Biotherapeutics GAAP EPS of -$0.23 beats by $0.02, revenue of $27.36M beats by $2.67M [5/9/2024 5:26 PM]	0.5370	-0.01 (-1.61%)	0.57	0.02 (4.43%)	0.20 - 2.54	1,804,936	1,230,000	147,849
Atara Biotherapeutics GAAP EPS of -$0.23 beats by $0.02, revenue of $27.36M beats by $2.67M [5/9/2024 5:26 PM]
28-03-2024	PM		ATRA	Atara Biotherapeutics, Inc.	68.28	-0.56	-0.61	-0.72	Atara Biotherapeutics GAAP EPS of -$0.56 misses by $0.03, revenue of $4.25M misses by $10.01M [3/28/2024 8:43 AM]	0.7072	0.01 (1.03%)	0.67	-0.03 (-3.73%)	0.20 - 3.08	1,096,273	1,420,000	25,384
Atara Biotherapeutics GAAP EPS of -$0.56 misses by $0.03, revenue of $4.25M misses by $10.01M [3/28/2024 8:43 AM]
01-11-2023	PM		ATRA	Atara Biotherapeutics	130.00	-0.66	-0.63	0.00		1.25	-0.04 (-2.71%)	1.31	0.02 (1.55%)	1.24 - 5.64	1,665,270	1,040,000	56,858
Atara licenses out US Tab-cel rights, plans to cut 30% of workforce [11/1/2023 11:11 AM] Mizuho values Atara's US tab-cel deal at $450M, or $4/share [11/1/2023 12:48 PM]
08-08-2023	AH		ATRA	Atara Biotherapeutics, Inc.	225.34	-0.68	-0.64	-0.31	Atara Biotherapeutics GAAP EPS of -$0.68 misses by $0.01, revenue of $0.96M misses by $2.81M [8/8/2023 4:21 PM]	1.88	-0.40 (-17.40%)	2.25	-0.02 (-0.88%)	1.45 - 5.94	1,182,594	1,350,000	13,406
Atara Biotherapeutics GAAP EPS of -$0.68 misses by $0.01, revenue of $0.96M misses by $2.81M [8/8/2023 4:21 PM]
08-05-2023	AH	4:00 PM ET (May 8)	ATRA	Atara Biotherapeutics, Inc.	265.73	-0.72	-0.40	-0.87	Atara Biotherapeutics GAAP EPS of -$0.72 misses by $0.36, revenue of $1.23M misses by $29.45M [5/8/2023 5:07 PM]	2.44	-0.54 (-18.01%)	2.94	-0.03 (-1.01%)	2.19 - 9.34	3,054,222	1,280,000	857
Atara Biotherapeutics GAAP EPS of -$0.72 misses by $0.36, revenue of $1.23M misses by $29.45M [5/8/2023 5:07 PM]
08-02-2023	AH	4:00 PM ET (Feb 8)	ATRA	Atara Biotherapeutics, Inc.	490.52	-0.72	-0.46	-0.96	Atara Biotherapeutics GAAP EPS of -$0.72 misses by $0.30, revenue of $0.22M misses by $39.45M [2/8/2023 4:02 PM]	4.76	-0.28 (-5.56%)	4.80	-0.24 (-4.76%)	2.83 - 16.07	1,087,059	900,000	8,044
Atara transfers rights for Ebvallo to Pierre Fabre in EU, certain other markets [2/8/2023 8:16 AM] Atara Biotherapeutics GAAP EPS of -$0.72 misses by $0.30, revenue of $0.22M misses by $39.45M [2/8/2023 4:02 PM]
08-11-2022	AH	4:00 PM ET (Nov 8)	ATRA	Atara Biotherapeutics, Inc.	438.78	-0.82	-0.78	-0.90	Atara Biotherapeutics GAAP EPS of -$0.82 misses by $0.03, revenue of $4.46M beats by $0.72M [11/8/2022 4:03 PM]	3.88	-1.02 (-20.71%)	4.68	-0.22 (-4.49%)	2.83 - 18.85	1,118,662	1,120,000	2,055
Atara Biotherapeutics GAAP EPS of -$0.82 misses by $0.03, revenue of $4.46M beats by $0.72M [11/8/2022 4:03 PM]
08-08-2022	AH	4:00 PM ET (Aug 8)	ATRA	Atara Biotherapeutics, Inc.	300.77	-0.31	-0.91	-0.91	Atara Biotherapeutics GAAP EPS of $0.18 beats by $1.14, revenue of $51.58M beats by $45.05M [8/8/2022 4:19 PM]	4.69	1.06 (29.20%)	3.85	0.22 (6.06%)	2.83 - 20.04	13,870,294	2,230,000	85,698
Atara Biotherapeutics GAAP EPS of $0.18 beats by $1.14, revenue of $51.58M beats by $45.05M [8/8/2022 4:19 PM] Atara stock rises ~27% on Q2 beat, US regulatory path for tab-cel; to cut 20% staff [8/9/2022 12:41 PM] Atara Biotherapeutics Announces Second Quarter 2022 Financial Results and Corporate Strategy Update [Aug-08-22 04:01PM]
05-05-2022	AH	4:05 PM ET (May 5)	ATRA	Atara Biotherapeutics, Inc.	646.10	-0.87	-0.98	-0.86	Atara Biotherapeutics GAAP EPS of -$0.87 beats by $0.14, revenue of $7.31M beats by $2.98M [5/5/2022 4:39 PM]	6.92	0.10 (1.47%)	6.82	0.0 (0.00%)	6.31 - 20.04	693,701	890,000	169,778
Atara Biotherapeutics GAAP EPS of -$0.87 beats by $0.14, revenue of $7.31M beats by $2.98M [5/5/2022 4:39 PM] Atara Biotherapeutics Announces First Quarter 2022 Financial Results and Operational Progress [May-05-22 04:01PM] Atara Biotherapeutics (ATRA) Reports Q1 Loss, Tops Revenue Estimates [May-05-22 05:25PM] Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [May-06-22 04:01PM]
28-02-2022	AH	4:00 PM ET (Feb 28)	ATRA	Atara Biotherapeutics, Inc.	1,190	-0.96	-0.60	-0.95	Atara Biotherapeutics GAAP EPS of -$0.96 misses by $0.37, revenue of $7.55M misses by $27.59M [2/28/2022 4:12 PM]	10.15	-2.70 (-21.01%)	12.68	-0.17 (-1.32%)	9.93 - 20.04	2,074,105	810,000	1,370
Atara Biotherapeutics GAAP EPS of -$0.96 misses by $0.37, revenue of $7.55M misses by $27.59M [2/28/2022 4:12 PM] Atara Biotherapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Operational Progress [Feb-28-22 04:05PM] Atara Biotherapeutics (ATRA) Reports Q4 Loss, Lags Revenue Estimates [Feb-28-22 05:55PM]
04-11-2021	PM	7:30 AM ET (Nov 4)	ATRA	Atara Biotherapeutics, Inc.	1,400	-0.90	-0.92	-0.92	Atara Biotherapeutics EPS beats by $0.06, beats on revenue [11/4/2021 7:35 AM]	19.89	1.14 (6.08%)	19.89	0.0 (0.00%)	11.81 - 28.20	948,631	650,000	9,491
Atara Biotherapeutics Q3 2021 Earnings Preview [11/3/2021 1:43 PM] Atara Biotherapeutics EPS beats by $0.06, beats on revenue [11/4/2021 7:35 AM] Atara Biotherapeutics Announces Third Quarter 2021 Financial Results and Operational Progress [Nov-04-21 07:30AM] Atara Biotherapeutics to Present Eight Abstracts at the 63rd American Society of Hematology (ASH) Annual Meeting, Including First Presentation of Tab-cel® Pivotal Phase 3 (ALLELE) Data [Nov-04-21 09:30AM] How Much Upside is Left in Atara Biotherapeutics (ATRA)? Wall Street Analysts Think 48% [Nov-04-21 10:35AM] Atara Biotherapeutics (ATRA) Reports Q3 Loss, Tops Revenue Estimates [Nov-04-21 10:25AM] Atara Biotherapeutics, inc (ATRA) Q3 2021 Earnings Call Transcript [Nov-04-21 04:01PM]
09-08-2021	AH	4:00 PM ET (Aug 9)	ATRA	Atara Biotherapeutics, Inc.	1,080	-0.91	-0.88	-1.14	Atara Biotherapeutics EPS beats by $0.02, misses on revenue [8/9/2021 4:03 PM]	12.75	0.26 (2.08%)	13.05	0.56 (4.48%)	11.33 - 28.20	925,166	550,000	4,162
Atara Biotherapeutics EPS beats by $0.02, misses on revenue [8/9/2021 4:03 PM] Atara Biotherapeutics adds Ameet Mallik to board of directors [8/9/2021 4:15 PM] Atara Biotherapeutics Appoints Cell Therapy and Oncology Commercialization Veteran Ameet Mallik to the Board of Directors [Aug-09-21 04:01PM] Atara Biotherapeutics Announces Second Quarter 2021 Financial Results and Operational Progress [Aug-09-21 04:02PM] Atara Biotherapeutics (ATRA) Reports Q2 Loss, Misses Revenue Estimates [Aug-09-21 05:25PM] Atara Biotherapeutics, inc (ATRA) Q2 2021 Earnings Call Transcript [Aug-09-21 09:30PM]
04-05-2021	AH	4:05 PM ET (May 4)	ATRA	Atara Biotherapeutics, Inc.	1,220	-0.86	-0.93	-1.20	Atara Biotherapeutics EPS beats by $0.08, beats on revenue [5/4/2021 4:27 PM]	13.51	-0.14 (-1.03%)	14.30	0.65 (4.76%)	8.39 - 28.20	695,339	1,120,000	7,230
Atara Biotherapeutics EPS beats by $0.08, beats on revenue [5/4/2021 4:27 PM] Atara Biotherapeutics, Inc. to Host Earnings Call [May-04-21 02:30PM] Atara Biotherapeutics Announces First Quarter 2021 Financial Results and Operational Progress [May-04-21 04:01PM] Atara Biotherapeutics (ATRA) Reports Q1 Loss, Lags Revenue Estimates [May-04-21 05:20PM]
01-03-2021	AH	4:00 PM ET (Mar 1)	ATRA	Atara Biotherapeutics, Inc.	1,380	-0.95	-0.73	-1.36	Atara Biotherapeutics EPS misses by $0.17 [3/1/2021 4:11 PM]	17.07	-0.04 (-0.20%)	16.70	-0.40 (-2.37%)	4.52 - 28.20	1,415,410	679,291	1,055
Atara Biotherapeutics EPS misses by $0.17 [3/1/2021 4:11 PM] Atara shares rise following Citi upgrade to buy [3/2/2021 1:03 PM] Atara Biotherapeutics Inc (ATRA) Q4 2020 Earnings Call Transcript [Mar-02-21 09:30AM] Atara Biotherapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Operational Progress [Mar-01-21 04:05PM] Atara Biotherapeutics, Inc. to Host Earnings Call [Mar-01-21 02:30PM]
09-11-2020	AH	4:00 PM ET (Nov 9)	ATRA	Atara Biotherapeutics, Inc.	1,030	-0.92	-1.10	-1.31	Atara Biotherapeutics EPS beats by $0.16 [11/9/2020 4:02 PM]	15.55	1.15 (7.99%)	14.88	0.48 (3.33%)	4.52 - 19.36	1,417,378	534,695	1,191

05-08-2020	AH	4:00 PM ET (Aug 5)	ATRA	Atara Biotherapeutics, Inc.	915.75	-1.14	-1.21	-1.60	Atara Biotherapeutics EPS in-line [8/5/2020 4:11 PM]	12.74	0.03 (0.24%)	13.50	0.79 (6.22%)	4.52 - 19.36	401,018	778,283	6,623

06-05-2020	AH		ATRA	Atara Biotherapeutics, Inc.	518.78	-1.20	-1.36	-1.44		0.0	0.0 (0.00%)	0.0	0.0 (0.00%)	0.0 - 0.0	0	0	0